Aduro Biotech, Inc. (NASDAQ:ADRO) COO Gregory W. Schafer sold 4,859 shares of the firm’s stock in a transaction that occurred on Wednesday, September 13th. The stock was sold at an average price of $10.99, for a total transaction of $53,400.41. Following the sale, the chief operating officer now owns 153,604 shares in the company, valued at approximately $1,688,107.96. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Shares of Aduro Biotech, Inc. (ADRO) traded up 0.90% during midday trading on Thursday, reaching $11.15. 609,127 shares of the company’s stock were exchanged. Aduro Biotech, Inc. has a one year low of $8.75 and a one year high of $15.52. The company’s 50-day moving average is $11.67 and its 200-day moving average is $10.97. The stock’s market cap is $831.92 million.

Aduro Biotech (NASDAQ:ADRO) last announced its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.02). The business had revenue of $5.90 million for the quarter, compared to analyst estimates of $3.98 million. Aduro Biotech had a negative return on equity of 43.92% and a negative net margin of 609.58%. The company’s quarterly revenue was down 84.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.03 earnings per share. Equities analysts expect that Aduro Biotech, Inc. will post ($1.37) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Aduro Biotech, Inc. (ADRO) COO Gregory W. Schafer Sells 4,859 Shares” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/09/14/aduro-biotech-inc-adro-coo-gregory-w-schafer-sells-4859-shares.html.

A number of equities research analysts have issued reports on the stock. BidaskClub raised shares of Aduro Biotech from a “hold” rating to a “buy” rating in a report on Tuesday, July 25th. Cowen and Company assumed coverage on shares of Aduro Biotech in a report on Tuesday, July 18th. They set an “outperform” rating for the company. Zacks Investment Research lowered shares of Aduro Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. HC Wainwright set a $18.00 price objective on shares of Aduro Biotech and gave the company a “buy” rating in a report on Thursday, August 3rd. Finally, Canaccord Genuity set a $30.00 price objective on shares of Aduro Biotech and gave the company a “buy” rating in a report on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. Aduro Biotech currently has a consensus rating of “Buy” and a consensus price target of $19.00.

Hedge funds have recently made changes to their positions in the company. Legal & General Group Plc raised its stake in shares of Aduro Biotech by 11.2% during the 2nd quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock worth $118,000 after buying an additional 1,043 shares during the period. Parametric Portfolio Associates LLC raised its stake in shares of Aduro Biotech by 15.9% during the 1st quarter. Parametric Portfolio Associates LLC now owns 15,424 shares of the biotechnology company’s stock worth $166,000 after buying an additional 2,119 shares during the period. Tudor Investment Corp ET AL raised its stake in shares of Aduro Biotech by 34.8% during the 1st quarter. Tudor Investment Corp ET AL now owns 15,436 shares of the biotechnology company’s stock worth $166,000 after buying an additional 3,984 shares during the period. Voya Investment Management LLC raised its stake in shares of Aduro Biotech by 15.3% during the 2nd quarter. Voya Investment Management LLC now owns 18,935 shares of the biotechnology company’s stock worth $216,000 after buying an additional 2,515 shares during the period. Finally, American International Group Inc. raised its stake in shares of Aduro Biotech by 7.1% during the 1st quarter. American International Group Inc. now owns 21,840 shares of the biotechnology company’s stock worth $235,000 after buying an additional 1,447 shares during the period. 35.05% of the stock is owned by institutional investors and hedge funds.

About Aduro Biotech

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Insider Buying and Selling by Quarter for Aduro Biotech (NASDAQ:ADRO)

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.